Nucleus, TIL

Podcast: TIL Therapy in Sarcoma: From Tumor Procurement to Clinical Response

In this episode of ASTCT Talks, host Daniel Olson, MD, medical oncologist and co-leader of the melanoma, sarcoma, and solid tumor cellular therapy programs at the University of Chicago, is joined by John Mullinax, MD, surgical oncologist at Moffitt Cancer Center, and Lauren Banks, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, to discuss the emerging role of tumor-infiltrating lymphocyte (TIL) therapy in sarcoma.

As TIL therapy expands beyond melanoma, investigators are exploring its potential in soft tissue sarcomas, including dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma. The conversation examines the scientific rationale for TIL therapy in sarcoma, early clinical results, and the unique surgical and operational considerations required to bring this cellular therapy approach to patients with solid tumors.

The discussion covers:

  • The unmet clinical need in sarcoma and why certain sarcoma subtypes may be particularly attractive candidates for TIL therapy.
  • Early clinical experience with TIL therapy in sarcoma and what the initial results may mean for future treatment approaches.
  • Practical considerations for tumor procurement, including lesion selection, surgical planning, and manufacturing success.
  • The multidisciplinary collaboration required among surgery, medical oncology, pathology, radiology, and cellular therapy teams to successfully deliver TIL therapy.

This episode provides clinical, translational, and operational perspectives on one of the most promising emerging applications of cellular therapy in solid tumors and explores what may be next for patients with sarcoma.

Listen to the episode below or on your favorite app. Subscribe to ASTCT Talks and share this episode with your colleagues to keep the conversation going.

This episode was made possible through support from Iovance.

Disclaimer: This episode is intended for educational purposes only. Discussion of investigational therapies or clinical trial results does not constitute a treatment recommendation or establish a standard of care.